Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Items 401–500 of 1,001
Anorexigenic Effects of GLP-1 and Its Analogues
Gallwitz, B. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_8 · Cited by 50
SUBBARAYAN, S. K., & Kipnes, M. S. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.580738 · Cited by 49
“The contribution of incretin factors to total insulin responses was shown to be ~ 72% in control subjects compared with 36% in diabetic patients [11].”
BackgroundPsaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 52
“47 In healthy individuals, GIP is thought to be the more dominant incretin; however, under hyperglycemic conditions inT2DM the effect of GIP is significantly reduced.”
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 49
Reduced postprandial GLP ‐1 responses in women with gestational diabetes mellitus
Bonde, L., Vilsbøll, T., Nielsen, T., Bagger, J. I., Svare, J., Holst, J. J., Larsen, S., & Knop, F. K. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12082 · Cited by 45
“Patients with type 2 diabetes exhibit a severely reduced incretin effect [2] and some studies have shown that postprandial secretion of GLP-1 may be reduced in some patients with type 2 diabetes [3,4].”
BackgroundNew combination treatments in the management of diabetes: focus on sitagliptin – metformin
Green, J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3105 · Cited by 42
“Importantly, it is understood that the incretin effect is diminished in individuals with type 2 diabetes (Nauck et al 1986).”
Saxagliptin overview: special focus on safety and adverse effects
Ali, S., & Fonseca, V. A. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.741584 · Cited by 43
“This phenomenon is called ‘incretin effect’ and is responsible for 70% of total insulin secretion in response to a meal [1,2].”
BackgroundNovel dual incretin agonist peptide with antidiabetic and neuroprotective potential
Pathak, N. M., Pathak, V., Gault, V. A., McClean, S., Irwin, N., & Flatt, P. R. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.021 · Cited by 43
Pontikis, C., Yavropoulou, M. P., Toulis, K. A., Kotsa, K., Kazakos, K., Papazisi, A., Gotzamani-Psarakou, A., & Yovos, J. G. (2011) · Journal of Women's Health · doi:10.1089/jwh.2010.2272 · Cited by 41
“The assays have 100% cross-reactivity to the intact forms of human GIP (1-42) and GLP-1 (7-36) and the inactive forms GIP (3-42) and GLP-1 (9-36) after N-terminal cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4).”
The evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
“The incretin effect describes the phenomenon that oral glucose leads to a greater insulin response than an isoglycaemic intravenous glucose load [8, 9].”
BackgroundReview of the Therapeutic Uses of Liraglutide
Ryan, G. J., Foster, K. T., & Johnson, L. M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.06.004 · Cited by 44
Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
Neumiller, J. J., & Campbell, R. K. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090555 · Cited by 42
“This phenomenon, termed the incretin effect, is due to the release of hormones from the intestinal tract and is capable of augmenting the release of insulin from the pancreas in a glucose-dependent manner.(9,10) The two incretin hormones linked to this effect are GIP, secreted mainly from duodenal K cells of the proxi…”
Backgroundβ-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity
Aulinger, B. A., Vahl, T. P., Wilson-Pérez, H. E., Prigeon, R. L., & D'Alessio, D. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4009 · Cited by 43
Manell, E., Hedenqvist, P., Svensson, A. C., & Jensen‐Waern, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148896 · Cited by 51
“GLP-1 analogues are widely used as medication for patients with T2D, and have recently also been suggested for treatment of T1D [23, 24].”
BackgroundInfluentialClinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment
Halabi, A., Maatouk, H., Siegler, K. E., Faisst, N., Lufft, V., & Klause, N. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.29 · Cited by 44
Incretin-based therapies in the treatment of type 2 diabetes — More than meets the eye?
Łabuzek, K., Kozłowski, M., Szkudłapski, D., Sikorska, P., Kozłowska-Geller, M. A., & Okopień, B. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.01.009 · Cited by 48
“The so-called incretin effect is a phenomenon in which glucose admitted in any way that bypasses the gut (for example intravenously) elicits a much lower insulin secretory response than oral admission [2,3].”
BackgroundWajcberg, E., & Tavaria, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802611832 · Cited by 41
“compared the insulin secretion after oral glucose administration between type 2 diabetic patients and matched healthy controls and showed that the enhanced insulin secretion after oral glucose was attenuated in patients with T2DM [11] .”
Backgroundde Graaf‐Roelfsema, E. (2013) · The Veterinary Journal · doi:10.1016/j.tvjl.2013.09.064 · Cited by 51
Chueire, V. B., & Muscelli, E. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000313 · Cited by 50
Update on cystic fibrosis-related diabetes
Stecenko, A. A., & Moran, A. (2010) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32833e8700 · Cited by 47
“response to an oral glucose load, with glucagon-like peptide (GLP-1) and gastric inhibitory peptide (GIP) accounting for ~90% of this response [3].”
BackgroundVan Citters, G. W., Kabir, M., Kim, S. P., Mittelman, S. D., Dea, M. K., Brubaker, P. L., & Bergman, R. N. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020002 · Cited by 43
Mari, A., Bagger, J. I., Ferrannini, E., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073154 · Cited by 40
“The incretin effect has been shown to be reduced in patients with type 2 diabetes (T2D) [1], in prediabetic states such as impaired glucose tolerance and in obese, insulin resistant subjects with NGT [2,3].”
BackgroundThe incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes
Oh, T. J., Kim, M. Y., Shin, J. Y., Lee, J. C., Kim, S., Park, K. S., & Cho, Y. M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12167 · Cited by 40
Russell-Jones, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02465.x · Cited by 40
Holst, J. J., & McGill, M. A. (2011) · Clinical Drug Investigation · doi:10.2165/11595370-000000000-00000 · Cited by 44
Effects of age and diet on glucose and insulin dynamics in the horse
Rapson, J., Schott, H. C., Nielsen, B. D., McCutcheon, L. J., Harris, P. A., & Geor, R. J. (2018) · Equine Veterinary Journal · doi:10.1111/evj.12812 · Cited by 40
Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells
Gray, S. M., Xin, Y., Ross, E. C., Chazotte, B. M., Capozzi, M. E., El, K., Svendsen, B., Ravn, P., Sloop, K. W., Tong, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014368 · Cited by 38
“The abbreviations used are: T2D, type 2 diabetes; APC, allophycocyanin; NP, nulliparous; MP, multiparous; ANOVA, analysis of variance; qPCR, quantitative PCR.”
BackgroundInfluentialAydin, K., Arusoglu, G., Koksal, G., Cinar, N., Yazgan Aksoy, D., & Yildiz, B. O. (2014) · Clinical Endocrinology · doi:10.1111/cen.12468 · Cited by 39
Yamane, S., Harada, N., Hamasaki, A., Muraoka, A., Joo, E., Suzuki, K., Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., et al. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00143.x · Cited by 42
Mining incretin hormone pathways for novel therapies
Wideman, R. D., & Kieffer, T. J. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.02.005 · Cited by 42
Campbell, R. K. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h459 · Cited by 45
Sinclair, E. M., & Drucker, D. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000155379.11926.e2 · Cited by 39
Augustyns, K., der Veken, P. V., & Haemers, A. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.10.1387 · Cited by 41
“The incretin effect is known to be reduced in patients with Type 2 diabetes [11].”
BackgroundEffect of Glycemia on Plasma Incretins and the Incretin Effect During Oral Glucose Tolerance Test
Salehi, M., Aulinger, B., & D’Alessio, D. A. (2012) · Diabetes · doi:10.2337/db11-1825 · Cited by 38
“To wit, the incretin effect has been reported as impaired in subjects with T2DM or impaired glucose tolerance (7,8) and enhanced in subjects after RYGB (9,10).”
BackgroundMovahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 47
Damdindorj, B., Dezaki, K., Kurashina, T., Sone, H., Rita, R., Kakei, M., & Yada, T. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.06.034 · Cited by 37
Gustducin couples fatty acid receptors to GLP-1 release in colon
Li, Y., Kokrashvili, Z., Mosinger, B., & Margolskee, R. F. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00471.2012 · Cited by 37
Kelly, A. T., Sheikh, S., Stefanovski, D., Peleckis, A. J., Nyirjesy, S. C., Eiel, J. N., Sidhaye, A. R., Localio, R., Gallop, R., León, D. D. D., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab365 · Cited by 39
The Identification of Novel Proteins That Interact With the GLP-1 Receptor and Restrain its Activity
Huang, X., Dai, F. F., Gaisano, G., Giglou, K., Han, J., Zhang, M., Kittanakom, S., Wong, V., Li, W., Showalter, A. D., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1047 · Cited by 45
Irwin, N., Hunter, K., Frizzell, N., & Flatt, P. R. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.11.007 · Cited by 39
Wang, T., Gou, Z., Wang, F., Ma, M., & Zhai, S.-D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103798 · Cited by 37
“In patients with T2DM, the incretin effect is reduced or in some cases, absent [1].”
BackgroundPharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 42
“It is well established that the incretin effect is diminished in patients with type 2 diabetes [76].”
BackgroundIndividualized Therapy for Type 2 Diabetes: Clinical Implications of Pharmacogenetic Data
Mannino, G. C., & Sesti, G. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-012-0002-7 · Cited by 45
“It has been shown that the incretin effect is impaired in individuals with T2DM [151–153], and therapeutic agents based on potentiation of incretin action provide new approaches for the treatment of T2DM [148].”
BackgroundIncretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
New technologies and therapies in the management of diabetes.
Triplitt, C. L. (2007) · PubMed · Cited by 44
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
“…that up to 70% of the insulin secretion in response to an oral glucose load is mediated by the actions of the incretin hormones, an observation referred to as the “incretin effect”; moreover, it is well known that in patients with T2D, the incretin effect is clearly reduced (Nauck et al., 1986).”
BackgroundKimura, T., Obata, A., Shimoda, M., Hirukawa, H., Kanda‐Kimura, Y., Nogami, Y., Kohara, K., Nakanishi, S., Mune, T., Kaku, K., et al. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.007 · Cited by 37
Guo, X.-H. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 33
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
Fadini, G. P., & Rigato, M. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s37644 · Cited by 36
“They play a crucial role in glucose homeostasis by enhancing pancreatic insulin secretion when glucose is taken orally (incretin effect) and by suppressing glucagon release and hepatic glucose output.(18) Both GLP-1 and glucose-dependent insulinotropic polypeptide are rapidly inactivated by DPP-4.”
BackgroundMansur, S. A., Mieczkowska, A., Flatt, P. R., Chappard, D., Irwin, N., & Mabilleau, G. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00051 · Cited by 41
“Previous studies have suggested that patients with T2DM have an attenuated response to endogenous GLP-1 and that infusion of exogenous synthetic GLP-1 could be considered a treatment option (13).”
BackgroundLe, T. D., Nguyen, N. P. T., Tran, T. T. H., Cong, T. L., Nguyen, L. H. T., Nhu, B. D., Nguyen, S. T., Ngo, M. V., Dinh, T. H., Nguyen, H. T., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s344532 · Cited by 41
New Therapeutic Strategies for the Treatment of Type 2 Diabetes Mellitus Based on Incretins
Gallwitz, B. (2005) · The Review of Diabetic Studies · doi:10.1900/rds.2005.2.61 · Cited by 44
“The incretin effect is known to be reduced in patients with type 2 diabetes, resulting in inappropriately low insulin secretion following oral ingestion of nutrients [33].”
BackgroundHarada, N., Hamasaki, A., Yamane, S., Muraoka, A., Joo, E., Fujita, K., & Inagaki, N. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00078.x · Cited by 37
Cypryk, K., Vilsbøll, T., Nadel, I., Smyczyńska, J., Holst, J. J., & Lewiñski, A. (2007) · Gynecological Endocrinology · doi:10.1080/09513590601137004 · Cited by 39
“give rise to very different plasma insulin concentrations in healthy individuals: only 30% of the insulin response following the OGTT is observed following the iIVGTT, which indicates that the incretin effect is responsible for up to 70% of the insulin response following oral ingestion of glucose [11,12].”
BackgroundDharmalingam, M., Sriram, U., & Baruah, M. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.77571 · Cited by 39
“Studies have shown that incretin pathways play a role in the progression of T2DM.”
BackgroundInfluentialOn the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Vilsbøll, T. (2004) · PubMed · Cited by 44
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Yang, Y.-S., Chen, H.-H., Huang, C.-N., Hsu, C. Y., Hu, K.-C., & Kao, C.-H. (2022) · Diabetes Care · doi:10.2337/dc21-1993 · Cited by 35
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Hansen, K. B., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02086.x · Cited by 35
Emerging gliptins for type 2 diabetes
Cahn, A., & Raz, I. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.807796 · Cited by 37
“In T2DM, the action of both incretin hormones is impaired [10].”
BackgroundParry, S. A., Smith, J. R., Corbett, T. R. B., Woods, R. M., & Hulston, C. J. (2017) · British Journal Of Nutrition · doi:10.1017/s0007114516004475 · Cited by 40
Kaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 59
“Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry.”
MethodHarnessing the Therapeutic Potential of Glucagon-Like Peptide-1: A Critical Review
Baggio, L. L., & Drucker, D. J. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201020-00005 · Cited by 36
Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes
Kozawa, J., Okita, K., Imagawa, A., Iwahashi, H., Holst, J. J., Yamagata, K., & Shimomura, I. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.134 · Cited by 36
“In this type of diabetes, incretin effect is reported to be severely reduced [3].”
BackgroundEriksen, M., Jensen, D. H., Tribler, S., Holst, J. J., Madsbad, S., & Krarup, T. (2015) · Diabetologia · doi:10.1007/s00125-015-3522-y · Cited by 36
The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents
Tsang, M.-W. (2012) · ISRN Endocrinology · doi:10.5402/2012/478120 · Cited by 40
“People with T2DM are known to have deficient meal-related incretin responses [4, 5], resulting in decreased insulin secretion, increased postprandial glucagon levels, and elevated postprandial glucose [39].”
BackgroundMarco‐Rius, I., von Morze, C., Sriram, R., Cao, P., Chang, G., Milshteyn, E., Bok, R., Ohliger, M. A., Pearce, D., Kurhanewicz, J. V., et al. (2016) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26525 · Cited by 36
“An equivalent quantity of intragastric glucose, as in normal meal ingestion, is associated with a much larger insulin response, by means of the incretin effect (25), i.”
“The next big thing” in diabetes: clinical progress on DPP‐IV inhibitors
von Geldern, T. W., & Trevillyan, J. M. (2006) · Drug Development Research · doi:10.1002/ddr.20138 · Cited by 40
“In contrast to GLP-1, glucose tolerance is not improved in T2DM patients treated with exogenous GIP [Nauck et al., 1993].”
InfluentialDipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review
Wani, J. H., John‐Kalarickal, J., & Fonseca, V. A. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.06.008 · Cited by 37
Wheeler, M. B., Gelling, R. W., Hinke, S. A., Tu, B., Pederson, R. A., Lynn, F., Ehses, J., & McIntosh, C. H. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.35.24593 · Cited by 35
Triplitt, C. L., Wright, A., & Chiquette, E. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.360 · Cited by 38
“The insulin response to a 50-g oral glucose load was compared by giving isoglycemic intravenous infusions to 14 patients with type 2 diabetes and eight matched, healthy control subjects.(29) Enhanced insulin secretion with oral 363”
MethodCracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
Hasib, A., Ng, M. T., Khan, D., Gault, V. A., Flatt, P. R., & Irwin, N. (2018) · Peptides · doi:10.1016/j.peptides.2017.10.015 · Cited by 34
“In this regard, the impaired incretin effect in man, representing a fundamental pathophysiological characteristic of type 2 diabetes [44], consists of two main elements, decreased GLP-1 secretion and defective insulinotropic action of the sister incretin hormone to GLP-1, glucosedependent insulinotropic polypeptide (G…”
BackgroundJepsen, S. L., Albrechtsen, N. J. W., Windeløv, J. A., Galsgaard, K. D., Hunt, J. E., Farb, T. B., Kissow, H., Pedersen, J., Deacon, C. F., Martin, R. E., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.143228 · Cited by 38
Dotson, C. D., Vigues, S., Steinle, N., & Munger, S. D. (2010) · PubMed · Cited by 45
Exenatide as a treatment for diabetes and obesity: Implications for cardiovascular risk reduction
Mafong, D. D., & Henry, R. R. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0009-z · Cited by 41
“An interesting phenomenon has been known for many years: the insulin response in healthy patients after an oral glucose load is greater than that seen after a matched quantity of is glucose given by intravenous infusion [ 9 ].”
Backgroundder Schueren, B. V., Homel, P., Alam, M., Agenor, K., Wang, G., Reilly, D., & Laferrère, B. (2011) · Diabetes Care · doi:10.2337/dc11-1472 · Cited by 36
“Participants, after signing an informed consent, underwent a 50-g 3-h OGTT, followed by an isoglycemic intravenous glucose challenge (isoG IVGT) to measure the incretin effect (6).”
MethodThe contribution of incretin hormones to the pathogenesis of type 2 diabetes
Meier, J. J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.007 · Cited by 46
Mossello, E., Ballini, E., Boncinelli, M., Monami, M., Lonetto, G., Mello, A. M., Tarantini, F., Baldasseroni, S., Mannucci, E., & Marchionni, N. (2011) · Experimental Diabetes Research · doi:10.1155/2011/281674 · Cited by 37
“It has been known for many years that T2DM is characterized by a severely reduced incretin effect, defined as the difference between insulin responses to oral and intravenous glucose administration [26].”
BackgroundType 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Aiysha Thompson, K. (2013) · Clinical & Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 33
“However, it was noted that glucose administered orally promoted a significantly greater insulin response than glucose administered intravenously (Figure 2), although plasma glucose levels were the same [38-40].”
BackgroundTriplitt, C. L., McGill, J. B., Porte, D., & Conner, C. S. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-c.1 · Cited by 39
“In contrast, plasma levels of GIP are normal or slightly elevated in T2DM, while its incretin activity is markedly defective or absent.(45,49,51,52) Thus, both impaired secretion of GLP-1 and defective activity of GIP contribute to the blunted incretin response in T2DM.”
Influence of circulating nesfatin-1, GSH and SOD on insulin secretion in the development of T2DM
Huang, K., Liang, Y., Wang, K., Wu, J., Luo, H., & Yi, B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.882686 · Cited by 36
“into the circulation from gut endocrine cells in response to food digestion and facilitate insulin secretion in a glucose-dependent manner (15, 16).”
BackgroundAlpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes
Calanna, S., Scicali, R., Pino, A. D., Knop, F. K., Piro, S., Rabuazzo, A. M., & Purrello, F. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0555-5 · Cited by 38
Plasma Incretin Levels and Dipeptidyl Peptidase-4 Activity in Patients with Obstructive Sleep Apnea
Matsumoto, T., Harada, N., Azuma, M., Chihara, Y., Murase, K., Tachikawa, R., Minami, T., Hamada, S., Tanizawa, K., Inouchi, M., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201510-697oc · Cited by 35
Ahn, C. H., Oh, T. J., Kwak, S. H., & Cho, Y. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13081 · Cited by 37
“After 60 minutes of glucose infusion, a physiological dose of GLP-1 (7-36) amide (0.”
BackgroundRecent advances of GIP and future horizons
Holst, J. J., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170230 · Cited by 33
Schou, J. H., Pilgaard, K. A., Vilsbøll, T., Jensen, C. B., Deacon, C. F., Holst, J. J., Vølund, A., Madsbad, S., & Vaag, A. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0382 · Cited by 33
Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity.
Nolen-Doerr, E., Stockman, M.-C., & Rizo, I. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00350-4 · Cited by 32
Gjesing, A. P., Ekstrøm, C. T., Eiberg, H., Urhammer, S. A., Holst, J. J., Pedersen, O. B., & Hansen, T. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2484-6 · Cited by 33
“While an absent or grossly impaired incretin effect characterises type 2 diabetes [21–23], the degree to which genetics regulate measures of the incretin system has been previously investigated in only one study, showing that genes accounted for 53% of the beta cell response to exogenous glucagon-like peptide-1 (GLP-1…”
BackgroundLack of insulinotropic effect of endogenous and exogenous cholecystokinin in man
Reimers, J., Nauck, M. A., Creutzfeldt, W., STRIETZEL, J., Ebert, R., Cantor, P., & Hoffmann, G. F. (1988) · Diabetologia · doi:10.1007/bf00277407 · Cited by 34
“In addition, insulinotropic gastrointestinal hormones are released, which stimulate pancreatic B cells via the enteroinsular axis [1, 2]. This phenomenon is called the incretin effect [3, 4] and is responsible for up to 60% of the amount of insulin secreted in response to an oral glucose load [ 5 , 6]. In man, gastric…”
BackgroundSelf-citationSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Pieters, I. C., Cahen, D. L., Diamant, M., & van Raalte, D. H. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009579 · Cited by 30
Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
Sjöholm, Å. (2010) · Pharmaceuticals · doi:10.3390/ph3030764 · Cited by 38
“Diabetes is a progressive disease characterised by impaired β-cell function, and reduced insulin sensitivity and secretion.”
BackgroundInfluentialIdorn, T., Knop, F. K., Jørgensen, M. B., Holst, J. J., Hornum, M., & Feldt‐Rasmussen, B. (2013) · Kidney International · doi:10.1038/ki.2012.460 · Cited by 34
Pinkney, J. H. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s7313 · Cited by 32
Regazzo, D., Barbot, M., Scaroni, C. M., Albiger, N. M. E., & Occhi, G. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09536-6 · Cited by 33
“In vivo, an impaired GIP/GIPR signaling with a blunted insulinotropic effect has been observed in patients with T2DM [37]: though it is still not clear whether this is a causative phenomenon or a consequence of GIPR downregulation induced by hyperglycemia, it might suggest a pathophysiological role of the incretin sys…”
BackgroundCushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A Review
DeFronzo, R. A., & Auchus, R. J. (2025) · Diabetes · doi:10.2337/db25-0120 · Cited by 34
Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study
Nakamura, Y., Inagaki, M., Shimizu, T., Fujita, K., Inoue, M., Gotoh, H., Oguchi, K., & Goto, Y. (2013) · Nephron Clinical Practice · doi:10.1159/000351678 · Cited by 31
Ohlsson, L., Alsalim, W., Carr, R. D., Tura, A., Pacini, G., Mari, A., & Åhrén, B. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12062 · Cited by 31
“The incretin effect accounts for more than 50% of the insulin secretion after oral glucose in humans [2] and experimental animals [3].”
BackgroundKishimoto, M., & Noda, M. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-115 · Cited by 32
“Several studies have shown that patients with type 2 diabetes generally exhibit attenuated GLP-1 secretion [34-37], although others have reported normal GLP-1 secretion in these patients [38,39].”
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.